Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Back on June 3, when Pfizer and Lilly both signed China deals on the same day, we wrote that the political rhetoric said decouple while the deal flow said accelerate, and that the two could not run in opposite directions forever. This week the gap started to close. The House Select Committee on China sent letters to the CEOs of the five biggest US pharma companies demanding details on the hundreds of clinical trials they run in China, with particular focus on sites in Xinjiang and at hospitals tied to the Chinese military. The committee was careful to say there is no evidence of wrongdoing. But the framing is unmistakable. Chairman John Moolenaar called China the cheapest and fastest place in the world to run early trials and questioned whether that speed is exposing American IP and aiding China's military biotech ambitions.

Here is why this matters more than a typical Washington letter. It arrives alongside the Biotech Investment National Security Act, which would put US licensing deals with Chinese firms under Treasury review and which explicitly names the Pfizer and BMS China deals as the kind it wants to stop. For the past six months, the smart money has treated the COINS Act and its successors as noise that would never catch up to the deal flow. That assumption is now being tested. If you run BD at a large pharma, the China licensing playbook that produced $138B in deals last year just got a new variable that is not going away before the midterms. The deals already signed are safe. The next ones now carry political risk that has to be priced in.

The market, for what it is worth, mostly shrugged. Lilly slipped 2.5% and AbbVie eased about 1% on the news, then both largely stabilized. That tells you investors see this as a slow building overhang, not an immediate threat. We think that read is right for now, but the direction of travel is clear, and this is the strongest signal yet that the China pipeline the whole industry leaned on is going to get more complicated, not less. 👉 Read Full Analysis

🌍 Policy

Washington put the industry's China pipeline under the microscope, and this time it named names. MRK | ABBV | LLY | PFE | BMY

The House Select Committee on China opened a national security investigation into the China clinical trials of the five largest US drugmakers. Chairman John Moolenaar sent letters to Merck and AbbVie on June 29, then to Lilly, Pfizer and BMS within days, giving all five until July 17 to respond. The committee wants details on due diligence, data protection, and IP safeguards, especially at trial sites in the Xinjiang region and at hospitals affiliated with China's military. The numbers it cited are specific: Merck has run 224 studies in China since 2005, including 40 at military tied sites; Pfizer has run at least 43 at military medical centers. The letters stop short of alleging any wrongdoing. Merck said patient safety and ethical integrity remain central to its research, and the Chinese embassy dismissed the probe as having "nothing credible" in it. Watch July 17, and watch whether this feeds momentum for the Biotech Investment National Security Act, which would route China licensing deals through Treasury review.

📊 Capital Markets

BridgeBio pulled in a billion dollars without selling a single new share. BBIO

BridgeBio secured $1B in preferred equity from Sixth Street Partners and KKR, one of the largest non dilutive financings of the year. The raise gives BridgeBio deep capital to push its rare disease and cardiology franchises, led by Attruby in ATTR cardiomyopathy, without diluting existing shareholders. It is also a signal about the financing environment: 40 private biotechs disclosed rounds of $100M or more in the first half of 2026, and big structured deals like this one show that capital is flowing to companies with commercial or near commercial assets. The money is there right now for the right story.

🔬 Cell Therapy

Orca Bio put a $428,000 price on its new blood cancer cell therapy. ORCA

Orca Bio set a $428,000 list price for Tregzi, a regulatory T cell therapy for blood cancer patients undergoing stem cell transplant. The pricing lands the drug in the same broad range as other one time cell therapies and reflects the manufacturing complexity of engineered T cell products. The launch adds a new tool for reducing transplant complications like graft versus host disease, and it is another sign that the cell therapy field is steadily moving from novelty to standard of care, with pricing to match.

🔬 Gene Therapy

Casgevy just reached younger kids, using the FDA's priority voucher program to get there. VRTX | CRSP

The FDA expanded Vertex and CRISPR's Casgevy into a younger pediatric population for sickle cell disease, broadening it beyond the 12 and up group it was first cleared for. Notably, the expansion came through the CNPV program, the priority voucher pathway we have tracked since it approved Foundayo in 50 days. Casgevy is the first CRISPR based medicine on the market, and reaching younger patients matters because earlier intervention can prevent the irreversible organ damage sickle cell causes over time. It is also a reminder that CNPV, whatever its transparency issues, keeps pulling meaningful approvals forward.

🔬 Research Integrity

Two pivotal retractions in two days is a pattern worth noting.

Nature retracted a widely cited study that linked lung cancer survival to the timing of PD-1 treatment, according to Fierce Pharma. On its own it is one paper. Coming one day after a top journal retracted the pivotal study behind Amgen's Tavneos, it points to something bigger: the evidence base underneath some marketed and widely used approaches is getting a harder second look. For anyone relying on published data to guide strategy or prescribing, the lesson of this week is that peer review is not the final word, and post publication scrutiny is now a real force.

📋 The Week in Review

👉 Read Full Analysis

We have tracked the China licensing wave all year, from BMS and Hengrui's $15.2B deal in May through Pfizer and Innovent's $10.5B in June, and we flagged repeatedly that the political counterweight was building even as the deals piled up. This week the counterweight got specific. Here is how we would think about the exposure.

The deals already signed are safe. Nothing in the committee's letters or the pending Biotech Investment National Security Act unwinds an existing agreement. The risk is entirely forward looking. It falls on the next wave of licensing deals and on trials still being placed in China.

Three tiers of exposure. Most exposed are companies with heavy trial footprints at military affiliated or Xinjiang sites, since those are the committee's explicit focus. Merck, with 224 China studies and 40 at military tied sites, and Pfizer, with at least 43 at military centers, are squarely in that group. Moderately exposed are companies with large China licensing deals but cleaner trial geographies. Least exposed are companies that have stayed out of China sourcing entirely, a group that until now looked like it was missing out and may soon look prudent.

What BD teams should do. Price political risk into the next China deal the way you already price clinical and regulatory risk. Map your own trial sites against the committee's criteria before a letter arrives, not after. And build the case now for why a given Chinese asset is worth the added scrutiny, because "it is cheaper and faster" is exactly the rationale the committee is attacking. The $138B that flowed into Chinese licensing last year was underwritten on an assumption of frictionless access. That assumption no longer holds.

The base case is still that the deal flow continues, because the science and the economics are too compelling to abandon and because Congress moves slowly. But the risk premium on China sourcing just went up, and it is not coming back down soon.

💊 Cell Therapy Pricing: Where Tregzi Fits

Orca Bio's $428,000 list price for Tregzi is worth watching because it helps set the band for the next generation of engineered cell therapies. It sits below the headline seven figure prices of some one time gene therapies but well above conventional biologics, in the range the market has come to accept for personalized cell products.

The strategic question for the field is durability of value. Tregzi is a regulatory T cell therapy aimed at reducing transplant complications like graft versus host disease. If it meaningfully cuts those complications, the price is defensible on total cost of care grounds, because transplant complications are enormously expensive to manage. Payers increasingly evaluate cell therapies on that basis rather than on sticker price alone.

For the wave of cell therapies coming behind it, Tregzi is a useful reference point. It signals that the market will support pricing in the mid six figures for products that solve a clear clinical problem in a defined population, without needing to reach the seven figure ceiling that draws political attention.

📊 BridgeBio's Financing Blueprint

BridgeBio's $1B preferred equity raise from Sixth Street and KKR is a template more commercial stage biotechs will study. Rather than issue common stock and dilute shareholders at a moment when it has a launched product gaining traction, BridgeBio tapped structured capital that sits above common equity but does not flood the share count.

This works when a company has a real commercial asset to underwrite against, in this case Attruby in ATTR cardiomyopathy. It does not work for a preclinical company with no revenue line. That is the dividing line in this financing environment: companies with commercial or near commercial assets have access to deep, creative, founder friendly capital, while earlier stage names still face dilutive rounds or the IPO gauntlet.

With 40 private biotechs raising $100M or more in the first half and structured deals like this one available to the commercial tier, the capital picture is genuinely healthy for companies that have de risked their lead asset. The financing drought is over for that group. It is not over for everyone.

📅 Catalyst Calendar

Congress put the industry's China pipeline under the microscope, and the counterweight we flagged in June finally has teeth. BridgeBio raised a billion without dilution. Cell therapy pricing crept up. And the week's second pivotal retraction says peer review is getting a harder look.

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →